HCP prescription intelligence.
Built for relationship-driven Rx growth.
When an MR leaves, the relationship data leaves with them. Managers cannot see which HCPs are at risk of switching, which products are gaining traction, or where targeted intervention would have the highest impact — until the prescription numbers move. By then, it's too late. Pharos RxFlow gives managers and MRs that visibility before the numbers move.
Pharos RxFlow · HCP-level prescription intelligence for relationship-driven Rx growth.
The relationship data
that lives only in MRs' heads.
Managing prescription data across a distributed field force is a persistent challenge. MRs maintain mental models of HCP relationships that live only in their heads. When an MR leaves, the relationship data leaves with them. Managers cannot see which HCPs are at risk of switching, which products are gaining traction, or where targeted intervention would have the highest impact — until the prescription numbers move. By then, it's too late. RxFlow gives managers and MRs that visibility before the numbers move.
Three capabilities. One tool.
HCP Relationship & Rx Tracking
Comprehensive visit history, prescription intent scoring, and product engagement record for each HCP. Every field interaction informed by prior engagement data. No more starting every HCP conversation from memory.
AI-Powered Call Analysis & Coaching
Post-visit notes analysed to surface objection patterns, competitor mentions, and prescription intent signals. Actionable next-step recommendations to help representatives convert interest into prescriptions.
Territory-Level Prescription Intelligence
Aggregated prescription signals and product coverage data at territory level. HCP switching risk visible. Product traction visible. Where targeted intervention will have the highest impact — visible.
What the engagement
actually looks like.
How Pharos RxFlow operationalises HCP relationship intelligence
A typical RxFlow deployment is triggered by one of three events: (1) a senior MR (medical representative) resigning with 60–200 HCP relationships that exist only in his mental model and notebook; (2) a new product launch where the marketing head needs to identify which HCPs are highest-propensity prescribers; or (3) a territory restructuring where prescription-traction data needs to be re-allocated across MRs.
HCP Relationship & Rx Tracking. Every HCP gets a structured profile: visit history (date, duration, materials shared, objections raised, samples left), prescription intent scoring (based on conversation analysis + post-visit Rx data correlation), product engagement record (which products has the HCP shown active interest in, which products have been objected to), and competitor mention log. When an MR leaves, the relationship data stays with the company.
AI-Powered Call Analysis & Coaching. Post-visit notes (text, voice-to-text, or app-submitted structured notes) are parsed by the AI layer to surface objection patterns (price, side-effect profile, prescription-restriction concerns), competitor mentions (which competing brands are being cited in conversations), and prescription intent signals (verbal commitments, "let me try one patient first" signals, "I'm waiting for the next prescribing guideline" signals). The output: a per-MR coaching dashboard that surfaces conversion blockers before the next visit.
Territory-Level Prescription Intelligence. Aggregated prescription signals roll up to territory and area-sales-manager level. ASMs see HCP switching risk (which HCPs are reducing prescriptions across the portfolio — early signal of competitive displacement), product traction (which products are accelerating in which territories — input to incentive design), and targeted intervention opportunities (which 5–15 HCPs in the territory would benefit most from a tailored engagement).
Compliance framework
RxFlow aligns with UCPMP (Uniform Code for Pharmaceutical Marketing Practices) 2024 — India's mandatory pharma marketing code — and equivalent international codes (IFPMA, EFPIA, PhRMA). HCP-engagement data is stored, accessed, and audited under compliance-aligned controls. The DPDP Act 2023 framework governs PII handling for HCP data.
Outcome targets
(1) HCP-relationship retention through MR transitions — measurable through prescription-continuity tracking; (2) Per-MR call conversion lift — typically 15–35% improvement in objection-to-prescription conversion; (3) Territory Rx-trend visibility — switching risk identification 30–60 days earlier than market-data lag.
How Pharos RxFlow connects
to the rest of Pharos.
RxFlow holds the HCP relationship layer. RouteIQ uses it for daily visit planning. Signal provides AI coaching on individual visits. Pulse surfaces the territory and management view.
Built for specific roles.
Nine modules. One intelligence layer.
Built for the specific frictions of pharma.
ICG's commercial and field force engagements run on RxFlow, RouteIQ, Gate, Signal, and Pulse — five tools that connect field activity to prescription outcomes.
Explore the full Pharos platform →Every ICG pharma engagement runs on some combination of these nine modules. The pilot engagement determines which ones are active from Day 1.
Start a pilot project →
Led by a pharma specialist.
IIT BHU-founded leadership team.
Every ICG pharma engagement is led personally by Aditi Tripathi — M.Pharm, IIT BHU — with Abhash, Deep and Rohit (Co-Founding Team) bringing the scientific rigour, delivery architecture and commercial lens built across 8+ years. IIT BHU pharmaceutical engineers at every level of the engagement.
60+ specialists. One process. Every deliverable in-house. Gurgaon, since 2018.
Abhash Kumar
Strategy Lead · IIT BHU + IIM Bangalore
Leads scientific strategy and quality governance. Sets the standard for scientific rigour across every engagement.
Profile →
Deep Das
Operations Lead · IIT BHU (B.Tech + M.Tech)
Owns the AI-powered delivery system — the multi-tenant operations layer that runs every pharma engagement on time and on spec.
Profile →
Rohit Gupta
Business & Growth Lead · IIT BHU + IIM Rohtak
Pharma engineer who owns business growth and the commercial lens connecting science to prescription outcomes.
Profile →
Aditi Tripathi
IIT BHU · M.Pharm
Aditi leads every pharma engagement end to end — from scoping the scientific writing architecture to governing quality across delivery. Her M.Pharm from IIT BHU means she doesn't need the science explained to her. "She explains it to everyone else."
See Pharos RxFlow live.
30-minute demo. No commitment.
The demo walks through hcp prescription intelligence on real (anonymised) pharma data. You see exactly how the tool fits the engagement before any commercial conversation.
